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Abstract 
   To overcome drug resistance and reduce the side effects of cisplatin, a widely used antineoplas-
tic agent, major efforts have been made to develop next generation platinum-based anticancer 
drugs. Because cisplatin-DNA adducts block RNA polymerase II unless removed by transcrip-
tion-coupled excision repair, compounds that react similarly but elude repair are desirable. The 
monofunctional platinum agent pyriplatin displays antitumor activity in mice, a cytotoxicity pro-
file in cell cultures distinct from that of cisplatin, and a unique in vitro transcription inhibition 
mechanism. In the present study, we incorporated pyriplatin globally or site-specifically into lu-
ciferase reporter vectors to examine its transcription inhibition profiles in live mammalian cells. 
Monofunctional pyriplatin reacted with plasmid DNA as efficiently as bifunctional cisplatin and 
inhibited transcription as strongly as cisplatin in various mammalian cells. Using repair-defective 
NER-, MMR-, and SSBR-deficient cells, we demonstrate that NER is mainly responsible for re-
moval of pyriplatin-DNA adducts. These findings reveal that the mechanism by which pyriplatin 
generates its antitumor activity is very similar to that of cisplatin, despite the chemically different 
nature of their DNA adducts, further supporting a role for monofunctional platinum anticancer 
agents in human cancer therapy. This information also provides support for the validity of the 
proposed mechanism of action of cisplatin and provides a rational basis for the design of more 
potent platinum anticancer drug candidates using a monofunctional DNA-damaging strategy. 
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Introduction 
   cis-Diamminedichloroplatinum(II) (cDDP, cisplatin) and its close analogues carboplatin and 
oxaliplatin are used to treat about half of all patients receiving chemotherapy for cancer (Figure 1) 
(1). Broader application of platinum-based anticancer drugs, however, is limited by intrinsic or 
acquired drug resistance and side effects including emetogenesis, nephrotoxicity, and neurotoxic-
ity. Extensive efforts have been made to synthesize and test new platinum-based anticancer 
agents, with the promise that compounds with improved antitumor activity and fewer toxic side 
effects will be discovered. 
   The mechanism of action of platinum(II) anticancer agents has been extensively explored, and 
many details of the cellular response to these compounds are now understood. Cisplatin attacks 
nuclear DNA to form Pt-DNA cross-links. The major adducts are intrastrand cis-{Pt(NH3)2}2+ 
cross-links including 1,2-d(GpG) cross-links, which efficiently block RNA polymerase II until 
removed by DNA damage repair pathways (2, 3). Besides the conventional bifunctional plati-
num-based anticancer drugs that contain two reactive sites for DNA-binding, another class of 
compounds, monofunctional platinum anticancer agents with only one DNA reactive site, have 
been developed and tested. Monofunctional platinum(II) complexes such as chlorodiethylene-
triamineplatinum(II) chloride {[PtCl(dien)]Cl} and [PtCl(NH3)3]Cl do not inhibit DNA-
dependent polymerases and are ineffective against cancer cells (4, 5). Another monofunctional 
compound, the aminophosphine-containing platinum(II) complex, cis-
[PtCl(C6H11NH(CH2)2PPh2-N,P)(C6H11NH(CH2)2PPh2-P)], binds rapidly to DNA forming mo-
nodentate adducts at guanine residues. Although this compound has demonstrated anticancer ac-
tivity, it only slightly inhibits DNA synthesis and has little influence on DNA conformation (6). 
Some monofunctional platinum(II)-polyamide complexes, designed for recognition of specific 
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DNA sequences, are capable of forming covalent bonds with DNA, but failed to evoke better cy-
totoxicity against cancer cells than cisplatin (7, 8). A series of cationic monofunctional plati-
num(II) complexes, cis-[Pt(NH3)2(N-donor)Cl]+, has been synthesized and analyzed, and some 
of the compounds demonstrated moderate biological activity against in vivo murine tumor mod-
els (9). Like cisplatin these complexes inhibit DNA polymerase despite their very different 
DNA-binding modality (10). The spectrum of activity of one of these compounds, cis-
diammine(pyridine)chloroplatinum(II) [cDPCP, or “pyriplatin” (Figure 1)], against a panel of 
human cancer cell lines differs significantly from those of cisplatin or oxaliplatin, rendering py-
riplatin a lead compound for generating new platinum anticancer drug candidates (11). 
   When attached to the N7 position of a guanine residue in duplex DNA, pyriplatin generates no 
significant structural distortion (12). An in vitro study revealed that pyriplatin is a substrate for 
nucleotide excision repair (NER), but it eludes this repair pathway much more readily than cis-
platin. Studies of RNA polymerase II activity on a DNA duplex containing a single cis-
{Pt(NH3)2(py)}2+-dG adduct revealed a transcription inhibition mechanism distinct from that of 
bifunctional platinum compounds like cisplatin (13). An X-ray crystal structure analysis indi-
cated that pyriplatin bound to the N-7 position of a guanosine residue can be accommodated in 
the Pol II active site, where it forms a standard Watson-Crick base pair with cytosine of the 
growing RNA strand. Blockage of subsequent pol II translocation from the damaged site leads to 
inhibition of the pol II transcribing complex. In contrast, for the cis-{Pt(NH3)2}2+ 1,2-d(GpG) 
cross-link, delivery of the damaged nucleosides to the active site is inhibited by a translocation 
barrier (14). Details of transcription inhibition by pyriplatin in live mammalian cells, especially 
in comparison to other bifunctional platinum-based anticancer drugs, and the repair pathways 
that are responsible for removal of pyriplatin-DNA adducts, remain to be elucidated, however.  
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   To address these deficiencies, we have in the present study investigated the transcription inhibi-
tion profiles of pyriplatin and compared them to those of cisplatin and oxaliplatin. We examined 
the ability of cisplatin, oxaliplatin, and pyriplatin to inhibit the transcription of a Gaussia lucife-
rase reporter gene, utilizing globally platinated expression vectors in live mammalian cells. Dif-
ferent repair-deficient cell lines, including NER-, mismatch repair (MMR)-, and single strand 
break repair (SSBR)-deficient cells, were utilized to reveal repair pathways that might be in-
volved in removal of pyriplatin-DNA adducts. In addition, a site-specific pyriplatin-dG adduct 
was incorporated into the Gaussia luciferase expression vector. The transcription inhibition ef-
fects from this single pyriplatin-dG adduct in a 3,986-bp plasmid, as well as the mechanisms by 
which the repair-deficient cells process the site-specific lesion, were investigated. Our results 
shed light on the transcription inhibition effects and repair mechanisms of pyriplatin-DNA ad-
ducts. Moreover, they provide details about the mechanisms by which this monofunctional plati-
num compound generates its antitumor activity and suggest how this activity can be improved in 
the design of novel anticancer drug candidates based on monofunctional platinum complexes. 
 
Materials and Methods 
Preparation of Globally Platinated Transcription Probes 
   For global platination experiments, 125 μg/ml (45.4 nM) of pGLuc, prepared as described in 
Supplementary Information, was treated with 0, 0.25, 0.51, 1.02, 2.04, 4.07 μM cisplatin, 0, 0.23, 
0.45, 0.91, 1.81, 3.63 μM oxaliplatin, or 0, 0.42, 0.84, 1.68, 3.36, 6.71 μM pyriplatin in 25 mM 
Na-HEPES, 10 mM NaCl, pH 7.4 buffer for 16 h at 37 °C in the dark. A control plasmid without 
platinum was treated similarly. The reaction mixtures were then dialyzed against water and sub-
sequently against TE buffer (10 mM Tris-HCl, 2 mM EDTA, pH 8.0) to remove unbound plati-
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num. Quantification of Pt content for these globally platinated plasmids was obtained by flame-
less atomic absorption spectroscopy on a Perkin-Elmer AAnalyst 600 system. DNA concentra-
tions were measured by UV-vis absorption spectroscopy at 260 nm on a HP 8453 UV-visible 
spectrometer. The number of platinum complexes bound per nucleotide, rb, was computed from 
this information.  
Preparation of a Pyriplatin Modified Insertion Strand 
   A 16-mer oligonucleotide containing a site-specific cis-{Pt(NH3)2(py)}2+-dG adduct was pre-
pared in the following manner. A 25.7 mM aqueous solution of pyriplatin was activated by addi-
tion of 0.98 equiv of AgNO3 followed by agitation for 8 h in the dark at room temperature. The 
suspension was centrifuged. To a 0.2 mM solution of 5’-CCTCCTCG*TCTCTTCC (Integrated 
DNA Technologies), where the asterisk denotes the base to be platinated, in 10 mM NaH2PO4, 
pH 6.3, was added 1.2 equiv of activated pyriplatin. The reaction mixture was incubated over-
night in the dark at 37 °C. The reaction was stopped by freezing the solution. The pyriplatin-
modified insertion strand was purified by ion exchange HPLC [Agilent 1200 HPLC system, 
Dionex DNAPac PA-100, linear gradient, 0.34 to 0.45 M NaCl in 25 mM Tris-HCl (pH 7.4) over 
11 min]. After purification, the platinated DNA solution was dialyzed against H2O and lyophi-
lized. The platination level was confirmed by UV-vis and atomic absorption spectroscopy, which 
yielded a Pt/DNA ratio of 1.03±0.01. The insertion strand was further analyzed for nucleotide 
composition by enzyme digestion to confirm the validity of the platination site following a pub-
lished previously protocol (data not shown) (15).  
Preparation of Site-Specifically Platinated Plasmids 
   Site-specifically platinated pGLuc8temG plasmid containing a cis-{Pt(NH3)2(py)}2+-dG adduct 
between the CMV promoter and the luciferase expression gene was prepared following the strat-
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egy published previously (16). The gapped plasmid was obtained with the use of Nt.BbvCI and 
Nt.BspQI nicking restriction enzymes (New England Biolabs), followed by annealing with 
excess 24-mer complementary strand to remove the nicked strand. A 300 µg quantity of 
pGLuc8temG plasmid was digested with 15 U of Nt.BbvCI at 37 °C for 1 h. The reaction mix-
ture was heated at 80 °C for 20 min to deactivate the enzyme and then extracted with phe-
nol/chloroform/isoamyl alcohol to remove the enzyme. The resulting aqueous phase was di-
alyzed against H2O overnight at 4 °C. The plasmid was further digested with 15 U Nt.BspQI at 
50 °C for 1 h, and the enzyme was heat-deactivated and removed by a phe-
nol/chloroform/isoamyl alcohol extraction. The nicked plasmid was mixed with 1000 equiv of 
complementary DNA strand 5’-TTTTGGAAGAGACGAGGAGGTTTT in a buffer of 10 mM 
Tris-HCl, 2 mM MgCl2, 0.4 M NaCl, pH 7.4, heated at 80 °C for 5 min, and subsequently cooled 
at 4 °C for 5 min for 10 cycles. The gapped plasmid was purified by isopycnic centrifugation us-
ing a CsCl gradient at 58,000 rpm, 20 °C for 24 h, and quantitated by UV-vis spectroscopy.  
   The 16-mer insertion strands, either containing a site-specific cis-{Pt(NH3)2(py)}2+-dG adduct 
or no platinum, were phosphorylated with T4 polynucleotide kinase at 37 °C for 3 h. The enzyme 
was removed by a phenol/chloroform/isoamyl alcohol extraction. The phosphorylated strands 
were ethanol-precipitated and stored at -80 °C at a concentration of 100 pmol/µL. A 120 µg 
quantity of the gapped plasmid was annealed with 100 equiv of the insertion strand in a buffer of 
10 mM Tris-HCl, 2 mM MgCl2, 0.4 M NaCl, pH 7.4 from 90 °C to 4 °C at -1 °C/min in a ther-
mocycler, followed by a ligation with 240 U T4 DNA ligase at 16 °C for 16 h. The platinated 
plasmid was dialyzed against H2O at 4 °C overnight and further purified by treatment with 30 U 
of BsmBI at 55 °C for 1 h. The closed-circular form of plasmid was purified and concentrated by 
isopycnic centrifugation, followed by n-butanol extraction and ethanol precipitation. The plas-
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mids were quantitated by a Quant-iTTM PicoGreen® dsDNA Kit (Invitrogen) and stored at -80 °C 
in TE buffer.  
   To carry out a restriction analysis on ligated platinated or unplatinated plasmids, a 60 ng quan-
tity of pGLuc8temG plasmid was incubated with 2 U BsmBI at 55 °C for 30 min. The plasmids 
were analyzed using 0.8% agarose gel electrophoresis containing 0.5 µg/mL ethidium bromide. 
The gels were documented with a BioRad Fluor-S MultiImager.  
Cell Lines and Tissue Culture 
    XPF (GM08437) cells were obtained from the Coriell Cell Depositories at Coriell Institute. 
XPFcorr cells were generously offered by Dr. Gan Wang at Wayne State University. U2OS-
MOCK and XPF-1128 cells were offered by Dr. Nora Graf in the Department of Chemistry at the 
Massachusetts Institute of Technology. PARP-1+/+ and PARP-1-/- mouse embryonic fibroblasts 
(MEFS) were kindly provided by Prof. Paul Chang at the Massachusetts Institute of Technology. 
HEC59 and HEC59+Chr2 cells were obtained from Dr. Thomas Kunkel from the National Insti-
tutes of Health. 
    All cells were grown in a humidified incubator at 37 °C under 5% CO2. XPF, U2OS-MOCK, 
and XPF-1128 cells were maintained in DMEM with 10% FBS, and 1% penicillin/streptomycin. 
XPFcorr cells were maintained in DMEM with 10% FBS, 0.5 mg/mL G418 sulfate, and 1% pe-
nicillin/streptomycin. HEC59 cells were grown in DMEM/F12 supplemented with 10% FBS and 
1% penicillin/streptomycin. HEC59+Chr2 cells were grown in DMEM/F12 supplemented with 
10% FBS, 1% penicillin/streptomycin, and 0.4 mg/mL G418 sulfate. PARP-1+/+ and PARP-1-/- 
MEFS were maintained in DMEM medium with 10% FBS and 1% penicillin/streptomycin. 
Transient Transfection of Cells and GLuc Reporter Transcription Assays 
   Transfection of the platinated plasmids into mammalian cells was carried out as reported pre-
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viously (17). The details are reported in the Supplementary Information section.  
 
Results 
Transcription Inhibition Strategy  
   To investigate the extent to which pyriplatin-DNA adducts inhibit transcription, and to gauge 
possible mechanisms for repairing its monofunctional adducts, transcription assays were carried 
out utilizing platinated mammalian expression vectors in live mammalian cells of different origin 
(Table S1). A Gaussia luciferase expression vector, pGLuc, which encodes a secretable form of 
the enzyme under control of a CMV promoter, was employed. Pyriplatin was incorporated into 
pGLuc either globally or site-specifically between the CMV promoter and the luciferase gene. 
Platinated and unplatinated control plasmids were transfected into cells using cationic liposomes. 
Subsequently, the cell media containing the secreted luciferase were collected at various time 
intervals. An advantage of the secreted luciferase system is that a time-dependent cellular re-
sponse to the platinated plasmids can be monitored without lysing the cells, as is necessary using 
other internal reporter enzyme systems (18, 19). The transcription inhibition activity of pyriplatin, 
and of cisplatin and oxaliplatin as controls, was determined by quantification of expressed lucife-
rase using coelenterazine as substrate. NER-, MMR-, and SSBR-deficient cells were employed 
both to monitor transcription inhibition activity of pyriplatin and to identify potential repair me-
chanisms of pyriplatin-DNA adducts in live cells.  
Construction of Globally Platinated Plasmids 
   pGLuc vectors were globally platinated with different platinum anticancer agents by allowing 
the plasmids to react with varying concentrations of the compounds in buffer. Platination levels 
were determined by atomic absorption and UV-vis spectroscopy (12). In Figure 2, the formal ra-
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tio of platinum to nucleotide in the reaction (rf) is plotted against the amount of platinum bound 
per nucleotide (rb) for cisplatin, oxaliplatin, and pyriplatin. The slope of the rb vs. rf plot for py-
riplatin is identical to that of cisplatin, but much larger than that for oxaliplatin. In other words, 
pyriplatin reacts with DNA as efficiently as cisplatin, and both compounds react more efficiently 
than oxaliplatin.  
Construction of a Plasmid Containing a Site-Specific Pyriplatin Monofunctional Adduct 
   A GLuc vector containing a site-specific cis-{Pt(NH3)2(py)}2+-dG adduct was constructed fol-
lowing the “gapping” strategy reported previously (16). pGLuc was modified to include two 
unique nicking restriction sites, Nt.BbvCI and Nt.BspQI, for incorporation of 16-mer insertion 
strands containing either a site-specific cis-{Pt(NH3)2(py)}2+-dG adduct or no platinum (Figure 
3). This new plasmid, pGLuc8temG, was then digested with the nicking restriction enzymes 
Nt.BbvCI and Nt.BspQI to obtain the desired gapped plasmid. The 16-mer insertion strands, con-
taining either a site-specific pyriplatin adduct or no platinum, were annealed and ligated into the 
gapped plasmids to form the final constructs. The site-specifically platinated and unplatinated 
control plasmids were designated as pGLuc8temG+IS-PtPy and pGLuc8temG+IS, respectively. 
Restriction analysis with BsmBI was carried out to confirm the presence of the monofunctional 
pyriplatin-DNA adduct, and the result is presented in Figure S1. The site-specific pyriplatin ad-
duct in the BsmBI restriction site efficiently inhibits the restriction digestion. 
Transcription Inhibition Profiles of Pyriplatin in NER-Deficient Cells 
   Transcription inhibition profiles were obtained for globally and site-specifically platinated 
probes in NER-deficient cells. Plasmids were transfected into XPF cells, which lack the XPF 
gene, and into XPFcorr cells, in which the XPF function was restored by introduction of the 
cDNA for XPF (20). pGLuc globally platinated with pyriplatin was examined first, and expres-
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sion levels were read after 8, 16, 24, 32, and 44 h of incubation. GLuc expression levels norma-
lized to that of unplatinated plasmid were plotted as a function of Pt/DNA ratios at various time 
points (Figure 4), or as a function of time at specific Pt/DNA ratios (Figure S2). After 44 h, the 
transcription levels were substantially restored in both cell lines, indicating repair of pyriplatin-
DNA adducts. There was stronger transcription inhibition by pyriplatin in XPF cells. For exam-
ple, at a Pt/DNA ratio of 23.2, the transcription level recovered from 19.8% at 8 h to 43.4% at 44 
h in XPF cells, whereas in XPFcorr cells, transcription recovered from 27.0% at 8 h to 56.3% at 
44 h. In addition, D0 values, where D0 is the number of Pt adducts per plasmid required to reduce 
transcription levels to 37% of control (21), were obtained to quantitate transcription inhibition 
differences between the two cell lines (Table 1). The increase in D0 values at different time points 
indicates restoration of transcription, and the higher D0 values in XPFcorr cells suggest a role for 
NER in repairing pyriplatin-DNA damage.  
   Transcription profiles of site-specifically platinated pGLuc in XPF and XPFcorr cells were also 
determined. The transcription levels from a plasmid carrying a single, site-specific pyriplatin-
DNA adduct were 37%, 49% and 54% in XPF cells, and 80%, 115% and 123% in XPFcorr cells 
at 24, 48, and 72 h, respectively. We also studied site-specific pGLuc plasmids containing a cis-
{Pt(NH3)2}2+ intrastrand 1,2-d(GpG) cross-link, the major type of cisplatin-DNA adduct, as a 
control. Transcription levels in the presence of the cis-{Pt(NH3)2}2+ 1,2-d(GpG) cross-link were 
53%, 59% and 62% in XPF cells, and 102%, 128% and 132% in XPFcorr cells at 24, 48, and 72 
h, respectively (Figure 5). Transcription levels greater than 100% after 48 h in XPFcorr cells for 
both cisplatin and pyriplatin suggest, perhaps, the stimulation of transcription from newly re-
paired plasmids. Restoration of XPF function significantly decreased the transcription inhibition 
induced by a site-specific pyriplatin-dG adduct, further confirming that NER can remove pyrip-
 American Association for Cancer Research Copyright © 2011 
 on August 2, 2012cancerres.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on December 16, 2011; DOI:10.1158/0008-5472.CAN-11-3151
  
12
latin adducts on DNA. The results from a cis-{Pt(NH3)2}2+ 1,2-d(GpG) cross-linked plasmid are 
in agreement with our previously published data (17), reinforcing the pivotal role of NER in the 
repair of cisplatin-DNA cross-links. It is noteworthy that a cis-{Pt(NH3)2(py)}2+-dG monofunc-
tional adduct inhibits transcription better than a cis-{Pt(NH3)2}2+ 1,2-d(GpG) cross-link in XPF 
cells.  
   Osteosarcoma cancer cells (U2OS) with downregulated XPF gene expression (22) were also 
examined. Transcription profiles of plasmids globally platinated with pyriplatin or oxaliplatin in 
XPF-normal (U2OS-MOCK) and XPF-knockdown (XPF-1128) cells are shown in Figures 6, S3, 
S4, and S5. For oxaliplatin, recovery of transcription occurred in both cell lines in a similar man-
ner over a 44 h time period (Figure S4), and there was stronger transcription inhibition in XPF-
1128 cells (Figure S5). For pyriplatin, there was little evidence of transcription recovery in 
U2OS-MOCK cells, and almost none in XPF-1128 cells (Figure S3). Stronger transcription inhi-
bition was also observed in XPF-1128 cells (Figure 6). Calculated D0 values for both oxaliplatin 
and pyriplatin are tabulated in Table S2. At most time points, pyriplatin has only slightly smaller 
D0 values than oxaliplatin in U2OS-MOCK cells and XPF-1128 cells. 
Transcription Inhibition Profiles of Pyriplatin in MMR-Deficient Cells 
   In addition to cells deficient in NER, MMR-deficient (HEC59) and -proficient (HEC59+Chr2) 
cells were examined in transient transfection assays with globally platinated plasmids in order to 
investigate the potential role of MMR in removing Pt-DNA adducts, including those from cispla-
tin, oxaliplatin, and pyriplatin. For cisplatin, there was slightly more transcription inhibition in 
MMR-proficient compared to -deficient cells over 44 h (Figure S6). Transcription levels in-
creased over 44 h in both HEC59 and HEC59+Chr2 cells. At an adduct level of 19.4 Pt/DNA, 
transcription increased from 19.2% to 35.2% of control in HEC59 cells and from 10.1% to 
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31.6% in HEC59+Chr2 cells (Figure S6). There was identical transcription inhibition of oxalipla-
tin in MMR-deficient and -proficient cells, and little recovery over time in both cell lines (Figure 
S7). As for pyriplatin-modified transcription probes, there were identical transcription profiles in 
both MMR-deficient and -proficient cells over 44 h, and slightly greater transcription inhibition 
occurred in HEC59+Chr2 cells (Figure 7). D0 values for cisplatin, oxaliplatin, and pyriplatin in 
both cell lines are shown in Table S3. Pyriplatin and cisplatin have identical D0 values in HEC59 
and HEC59+Chr2 cells, and the values are greater than those of oxaliplatin. There was a small 
increase in D0 from 8 h to 44 h in both cell lines for cisplatin, oxaliplatin, and pyriplatin. D0 val-
ues were slightly smaller in MMR-proficient cells, especially for cisplatin and pyriplatin.  
   Transcription assays with site-specifically platinated plasmids showed identical results to those 
obtained for globally platinated transcription probes. Site-specific pGLuc plasmids containing a 
cis-{Pt(NH3)2}2+ 1,2-d(GpG) cross-link or a cis-{Pt(NH3)2(py)}2+-dG monofunctional adduct 
were examined. Transcription levels were determined after 24, 48, and 72 h (Figure S8). The 
transcription inhibition effects of the cis-{Pt(NH3)2(py)}2+-dG adduct were identical to those of a 
cis-{Pt(NH3)2}2+ 1,2-d(GpG) cross-link in both HEC59 and HEC59+Chr2 cells. There was a 
small increase in transcription inhibition by pyriplatin in HEC59+Chr2 cells. The transcription 
levels in the presence of a cis-{Pt(NH3)2}2+ 1,2-d(GpG) cross-link were 66%, 76%, and 90% in 
HEC59 cells, and 65%, 76%, and 89% in HEC59+Chr2 cells at 24, 48, and 72 h, respectively 
(Figure S8).  
Transcription Inhibition Profiles of Pyriplatin in PARP-Knockdown Cells 
   PARP-1 knockdown mouse embryonic fibroblasts (MEFS) were studied to reveal the transcrip-
tion inhibition profiles of cisplatin, oxaliplatin, and pyriplatin. A small recovery in transcription 
levels was observed for all three platinum compounds tested, especially in PARP-1+/+ cells (Fig-
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ures S9, S10). Pyriplatin had D0 values identical to those of cisplatin and oxaliplatin in PARP-
1+/+ and PARP-1-/- cells (Table S4), further indicating that pyriplatin inhibits transcription as 
strongly as cisplatin and oxaliplatin. A slight increase of D0 values occurred from 8 h and 44 h in 
both cell lines for cisplatin, oxaliplatin, and pyriplatin, and the D0 values were slightly smaller in 
PARP-1-/- cells. 
   The transcription profiles of site-specifically platinated pGLuc in PARP-1+/+ and PARP-1-/- 
cells were also determined. Transcription levels in the presence of a site-specific cis-
{Pt(NH3)2(py)}2+-dG adduct were 46%, 56% and 76% in PARP-1+/+ cells, and 61%, 72% and 
77% in PARP-1-/- cells at 24, 48, and 72 h, respectively. The transcription levels in the presence 
of a cis-{Pt(NH3)2}2+ 1,2-d(GpG) cross-link were 52%, 60% and 67% in PARP-1+/+ cells, and 
61%, 77% and 84% in PARP-1-/- at 24, 48, and 72 h, respectively (Figure S11). A cis-
{Pt(NH3)2(py)}2+-dG adduct inhibited transcription as well as a cis-{Pt(NH3)2}2+ 1,2-d(GpG) 
cross-link in both PARP-1+/+ and PARP-1-/- cells. 
 
Discussion 
   Transcription inhibition is one of the major consequences of platinum-DNA damage, and there 
is a correlation between transcription inhibition by platinum compounds and their efficacy as an-
ticancer agents (23, 24). Numerous reports have presented the transcription inhibition of bifunc-
tional platinum antitumor compounds through reconstituted systems or studies in cell extracts or 
culture. Different mechanisms of transcription inhibition have been proposed, including hijack-
ing of transcription factors, physical blocking of RNA polymerases, and disruption of chromatin 
structure (24). Knowledge of transcription inhibition at monofunctional platinum-DNA adducts 
in the cell is, however, very limited. Monofunctional adducts at guanine residues formed by cis-
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[PtCl(NH3)2(N7-ACV) [ACV=acyclovir,  or 9-(2-hydroxyethoxymethyl)guanine], an active anti-
viral and antitumor compound, terminate DNA and RNA synthesis in vitro (25, 26). Other mono-
functional platinum(II) compounds, such as [PtCl(dien)]Cl and [Pt(NH3)3Cl]Cl, or monofunc-
tional adducts of cisplatin, were unable to inhibit RNA (27-29) or DNA (5) polymerase activity 
in vitro. Pyriplatin effectively blocked RNA synthesis in vitro, and a detailed mechanism of how 
this monofunctional platinum antineoplastic compound can inhibit pol II has been put forth (13). 
The present study significantly extends our knowledge of transcription inhibition by monofunc-
tional platinum anticancer agents to live mammalian cells and provides important information 
about which repair pathways remove monofunctional Pt-DNA adducts. 
Transcription Inhibition of Pyriplatin in NER-Deficient Cells  
   NER is considered the major pathway for removing cisplatin-DNA 1,2-d(GpG) intrastrand 
cross-links (3, 30, 31). There are two sub-pathways in NER, namely, transcription-coupled NER 
(TC-NER) and global genome NER (GG-NER). TC-NER-deficient cells are hypersensitive to 
cisplatin, indicating its critical role in the platinum-DNA damage response (30). The transcrip-
tion inhibition profile of a reporter gene containing global cisplatin cross-links, or a site-specific 
cisplatin cross-link, is dramatically different in XPF and XPFcorr cells (17). Here we studied the 
transcription inhibition profiles of oxaliplatin and pyriplatin in NER-deficient cells including 
XPF cells. Transcription of a globally pyriplatin-damaged reporter gene recovers slightly over 44 
h, and greater transcription inhibition occurs in XPF cells, indicating a role of NER in the repair 
of pyriplatin-DNA damage. Compared to the transcription inhibition of cisplatin in XPF and 
XPFcorr cells that we reported previously (17), however, pyriplatin does not evoke significant 
transcription recovery with time when globally platinated plasmids were utilized, indicating that 
pyriplatin-dG adducts are more difficult for the cellular machinery to recognize and repair. We 
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also incorporated pyriplatin site-specifically into the pGLuc plasmid between the CMV promoter 
and the GLuc expression gene to evaluate whether a pyriplatin-DNA adduct can act as a road-
block to the transcribing pol II complex in live cells. Robust transcription inhibition by a single 
pyriplatin-dG adduct was observed in XPF cells. Restoration of the XPF function significantly 
restored the transcription levels of luciferase from a plasmid site-specifically modified with py-
riplatin. Identical results were obtained from plasmids globally platinated with pyriplatin in XPF-
knockdown cells, strongly supporting our conclusion that NER plays a key role in the repair of 
pyriplatin-DNA damage. Moreover, pyriplatin inhibited transcription as effectively as oxaliplatin 
in U2OS cells, despite their NER deficient status.  
Transcription Inhibition of Platinum Compounds in MMR-Deficient Cells 
   MMR corrects single base mismatches and looped intermediates generated from DNA polyme-
rase slippage during replication and combination, as well as some forms of DNA damage by en-
dogenous or exogenous toxicants (32). DNA mismatches are recognized by hMutSα, a hetero-
dimer of hMSH2 and hMSH6, and hMutSβ, a heterodimer of hMSH2 and hMSH3. The binding 
of MMR proteins to different types of platinum-DNA adducts has been studied in vitro. hMSH2 
binds with some specificity to DNA globally damaged by cisplatin, and hMutSα recognizes cis-
platin 1,2-d(GpG) but not 1,3-d(GpTpG) cross-links (33-35). Cell-based studies revealed that 
MMR-deficiency is correlated with cisplatin resistance (36, 37). This line of evidence, together 
with other findings, implies that, in addition to the role of MMR in platinum damage repair, 
MMR proteins bind to cisplatin-DNA damage and initiate a signal transduction pathway leading 
to cell cycle arrest and apoptosis (38).  
We examined endometrial HEC59 (hMSH2-deficient) and HEC59+Chr2 (hMSH2-proficient) 
adenocarcinoma cells to investigate the transcription inhibition of pyriplatin, as well as the po-
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tential role of MMR in the repair or processing cisplatin, oxaliplatin, and pyriplatin lesions. 
Transcription assays with globally platinated plasmids indicated the inhibitory effects of cisplatin 
and pyriplatin to be greater in hMSH2-proficient cells. When D0 values are considered, pyriplatin 
is as active as cisplatin in inhibiting transcription of a reporter gene, and oxaliplatin is the most 
active compound in these cells. Platinum-DNA adducts from cisplatin and pyriplatin are slightly 
better transcription inhibitors in hMSH2-proficient cells, and no significant difference was ob-
served between hMSH2-deficient and proficient cells when oxaliplatin plasmids were employed 
(Table S3). These results further demonstrate that MMR may play a role, albeit a minor one, in 
mediating the cytotoxicity of cisplatin and pyriplatin. The results are in agreement with a pre-
vious model in which MMR proteins bind to cisplatin-DNA cross-links but not those from oxa-
liplatin (39). When site-specifically platinated plasmids were utilized, there were identical tran-
scription inhibition effects for a cisplatin 1,2-d(GpG) cross-link in hMSH2-deficient and –
proficient cells. A cis-{Pt(NH3)2(py)}2+-dG adduct, which is as active as a cisplatin 1,2-d(GpG) 
cross-link in blocking RNA synthesis, had a moderately stronger transcription inhibition effect in 
hMSH2-proficient cells. Taken together, these results suggest that MMR, instead of being the 
major repair pathway for removing pyriplatin-DNA adducts, may play a role in initiating apopto-
sis signaling pathways in response to pyriplatin-DNA damage.  
Transcription Inhibition of Platinum Compounds in PARP-1-Knockdown Cells 
   PARP-1 is one of the most abundant nuclear proteins in eukaryotes. The cellular functions of 
PARP-1 include modulation of chromatin structure and transcription, as well as DNA repair 
housekeeping (40). When genomic DNA is mildly damaged, PARP-1 is fully activated to recruit 
repair machinery and signal downstream effectors (41, 42). PARP-1 mainly detects single strand 
breaks (SSB), obligatory intermediates in base excision repair (BER) and NER. PARP-1 thus 
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participates actively in BER, and there is accumulating evidence for a role in NER (43). The af-
finity of PARP-1 for cisplatin-damaged DNA has been established by photocross-linking studies, 
and in vitro binding assays further revealed the binding of PARP-1 to DNA damaged by cisplatin, 
oxaliplatin, and pyriplatin (44-47). The transcription inhibition effects of pyriplatin in PARP-1 
knockdown cells and the question of whether or not PARP-1 has a significant function in the re-
pair of pyriplatin-DNA adducts in live cells have never been explored until now.  
   To investigate these possibilities, we utilized PARP-1-knockdown MEFS to reveal the tran-
scription inhibition profile of pyriplatin and the possible role of PARP-1 in repairing pyriplatin-
DNA adducts. Our results from globally platinated plasmids demonstrate that pyriplatin has iden-
tical D0 values compared to cisplatin and oxaliplatin; thus pyriplatin, once it binds to DNA, inhi-
bits transcription as efficiently as these FDA-approved platinum drugs. Cisplatin and oxaliplatin 
display greater transcription inhibition in PARP-1-/- cells at both high and low numbers of plati-
num adducts on the plasmids, implying a role for PARP-1 in repair of cisplatin- or oxaliplatin-
damaged DNA (Figure S9). When plasmids globally platinated with pyriplatin were examined, 
transcription inhibition levels were not notably different for PARP-1 normal vs. knockdown cells, 
especially at 12.5 and 23.2 Pt/DNA (Figure S10), suggesting that SSBR may not be a determina-
tive repair pathway in response to pyriplatin damage. We also used site-specifically platinated 
plasmids in this reporter assay. Transcription inhibition effects were slightly lower in the PARP-1 
knockdown cells for plasmids containing a site-specific cis-{Pt(NH3)2}2+ 1,2-d(GpG) cross-link 
or a cis-{Pt(NH3)2(py)}2+-dG adduct (Figure S11). Nevertheless, the transcription inhibition ef-
fects of the monofunctional platinum dG adduct are as strong as those of the bifunctional plati-
num 1,2-d(GpG) cross-link. One explanation for the difference between the results from globally 
and site-specifically platinated plasmids is that PARP-1 is not fully activated by a single plati-
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num present on the plasmid. The protein may still bind to the adduct, however, possibly shielding 
the damage from repair. Such an outcome would result in greater transcription inhibition in 
PARP-1 normal cells. The results from globally and site-specifically platinated plasmids suggest 
that SSBR is not the major repair pathway to remove pyriplatin-DNA adducts.  
Implications for the Mechanism of Action of Cisplatin and Suggestions for Improvement of 
Monofunctional Platinum Anticancer Agents 
   The mechanism of cisplatin action is a multistep process including cell entry, activation, DNA 
binding, and subsequent cellular responses (2, 3). Cisplatin is transported across the plasma 
membrane by both passive diffusion and carrier-mediated active transport. Once cisplatin enters 
cells, the relatively low chloride ion concentration of the cytosol favors the formation of acti-
vated aquated species. This active form of cisplatin subsequently attacks nucleophilic centers 
such as DNA bases, which are mainly responsible for the cytotoxicity of the drug. Cisplatin can 
also bind other molecules such as glutathione or metallothionein, processes that deactivate the 
compound. Formation of the platinum-DNA cross-links induces a complex series of cellular res-
ponses, including transcription inhibition, cell cycle arrest, and apoptosis. Remarkably, the mo-
nofunctional compound pyriplatin appears to have a mechanism of action very similar if not 
identical to that of cisplatin. This commonality of mechanism despite dramatically different 
structures for the Pt-DNA adducts, provide support for the current consensus mechanism of the 
platinum anticancer drugs (1).  
   Previous reports reveal that pyriplatin is an excellent substrate for organic cation transporters 
(OCTs) (12) but that the potency of pyriplatin is lower than that of cisplatin against ovarian, 
breast, and a variety of other types of cancer cells (11). From the present results, we conclude 
that pyriplatin binds to DNA in cancer cells as efficiently as cisplatin. Pyriplatin, once bound to 
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DNA, inhibits transcription as strongly as cisplatin, and pyriplatin-DNA adducts are more diffi-
cult to remove by the cellular repair machinery. NER is mainly responsible for removal of pyrip-
latin-DNA adducts.  
Because pyriplatin and cisplatin share similar DNA binding, transcription inhibition, and re-
pair pathways, we propose three possible reasons to account for the lower cytotoxicity of pyrip-
latin compared to cisplatin. Firstly, the cell may not accumulate pyriplatin as well as cisplatin. 
Although taken up by OCTs, pyriplatin may not pass as readily into the cytoplasm and nucleus of 
the cell. Secondly, pyriplatin may be deactivated more readily prior to DNA binding. Thirdly, 
transcription inhibition by pyriplatin may not correlate with its cytotoxicity, which we believe to 
be unlikely in mammalian systems. This analysis, combined with previous results on the struc-
tures of site-specifically modified DNA, including a transcription complex with Pol II, has 
guided the rational design of significantly more potent monofunctional platinum anticancer 
agents (12, 13).  In particular, as will be described elsewhere, monofunctional cationic platinum 
complexes bearing more extended aromatic fused ring heterocyclic ligands than pyridine have 
recently been obtained that significantly exceed the level of cisplatin cytotoxicity (48). Such 
compounds are currently being evaluated in pre-clinical studies for possible development as 
next-generation platinum anticancer drugs.  
Summary and Conclusion 
   In these studies we established transcription inhibition profiles for pyriplatin-DNA adducts in 
NER-, MMR- and SSBR-deficient cells, as well as in the corresponding repair-proficient cells. 
Gaussia luciferase reporters were used to measure the effects of pyriplatin modification of DNA, 
and plasmid-based reporter assays allowed us to examine transcription inhibition by pyriplatin 
and the DNA repair capacity in live cells. Pyriplatin reacts with plasmid DNA as efficiently as 
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cisplatin and significantly more so than oxaliplatin. It inhibits transcription in live cells to the 
same extent as cisplatin when globally platinated plasmids were utilized. A single, site-specific 
cis-{Pt(NH3)2(py)}2+-dG adduct within the 3,986-bp plasmid dramatically inhibits transcription, 
at least as strongly as a cis-{Pt(NH3)2}2+ 1,2-d(GpG) cross-link. NER, rather than MMR or 
SSBR, plays the most important role in removing pyriplatin-DNA adducts. We provide the first 
evidence that a monofunctional platinum anticancer agent can block RNA synthesis as efficiently 
as traditional bifunctional platinum anticancer drugs in live mammalian cells, and our data sug-
gest that the repair mechanism of the monofunctional platinum compounds might be similar to 
that of bifunctional platinum compounds. Our findings support a role for monofunctional plati-
num anticancer agents in cancer chemotherapy. Because pyriplatin can react with DNA to a level 
similar to that of cisplatin and, when bound to DNA, inhibit transcription as effectively as cispla-
tin, monofunctional platinum compounds with improved cellular uptake and reduced ability to 
bind cellular targets not associated with cytotoxicity may prove to be a promising route to novel 
platinum-based therapies.  
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Tables 
Table 1. D0 valuesa of globally platinated probes with pyriplatin assayed at different time inter-
vals after transfection for XPF and XPFcorr cells. 
Time after 
Transfection (h)
XPF 
(Pt/plasmid) 
XPFcorr 
(Pt/plasmid) 
8 14.12 ± 2.82 17.45 ± 1.35
16 17.30 ± 2.61 19.93 ± 0.86
24 19.60 ± 1.99 21.86 ± 1.21
32 21.22 ± 1.91 23.85 ± 1.23
44 22.34 ± 2.05 26.16 ± 1.28
a D0 value is defined as the number of Pt lesions per plasmid required to reduce transcription le-
vels to 37% of the control. 
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Figure 1. Chemical structures of platinum(II) anticancer agents cisplatin, oxaliplatin, and pyrip-
latin. 
 
 
 
Figure 2. Plots of rb vs. rf determined for pyriplatin, cisplatin, and oxaliplatin using pGLuc 
plasmid DNA.  
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5’--AGCTGAGGAAGAGACGAGGAGGCGAAGAGCGATC--  
  --TCGACTCCTTCTCTGCTCCTCCGCTTCTCGCTAG--  
CMV GLuc 
promoter platination region reporter gene poly(A) 
Nt.BbvCI Nt.BspQI 
BsmBI 
pGLuc8temG 
 
Figure 3. DNA sequence for building a site-specifically platinated Gaussia luciferase reporter 
containing a pyriplatin-dG adduct; the platination site is highlighted in bold. 
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Figure 4. Transcription profiles of globally platinated probes with pyriplatin in (A) XPF and (B)  
XPFcorr cells at 8 h (), 16 h (), 24 h (Δ), 32 h ( ), and 44 h (). (C) Transcription inhibition 
by pyriplatin at average loadings of 12.5, 23.2, and 44.1 platinum atoms per plasmid at 44 h in 
XPF and XPFcorr cells; *, P < 0.05; **, P < 0.01.
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Figure 5. Transcription profiles of site-specifically platinated probes containing a cis-
{Pt(NH3)2(py)}2+-dG adduct or a cis-{Pt(NH3)2}2+ 1,2-d(GpG) intrastrand cross-link in XPF and 
XPFcorr cells. 
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Figure 6. Transcription inhibition by pyriplatin at average loadings of 12.5 (upper left), 23.2 
(upper right), 44.1 (lower left), and 86.8 (lower right) platinum atoms per plasmid in U2OS-
MOCK and XPF-1128 cells; ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 
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Figure 7. Transcription inhibition by pyriplatin in MMR-deficient (HEC59) and proficient 
(HEC59+Chr2) cells. (A) Transcription profiles of globally platinated probes as a function of Pt 
adducts/DNA at 8 h (), 16 h (), 24 h (Δ), 32 h ( ), and 44 h (). (B) Transcription inhibition 
of pyriplatin at 12.5 and 23.2 Pt adducts/DNA as a function of time. 
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